Investigating the etiology and progression of acute myeloid leukemias
Our laboratory is determined to transform fundamental basic research discoveries into better diagnostic and clinical tools. We focus on acute myeloid leukemias and investigate how genetic lesions and changes in chromosomal structure contribute to disease progression. We are particularly interested in the role of translocations on transcription factor complexes. Our goal is to improve clinical care for pediatric patients diagnosed with acute myeloid leukemia.
Our laboratory focuses on exploring the underlying molecular mechanism of one of the more common variants of human myeloid leukemias, core-binding factor acute myeloid leukemia (CBF-AML) with t(8;21) translocation. Core-binding factor acute myeloid leukemias arise via chromosomal rearrangements impairing activity of genes encoding for proteins essential for normal blood cell development. Patients with core-binding factor leukemia have a massive accumulation of abnormal cells known as myeloid blasts, including a shortage of mature blood cells.
Chromosomal rearrangements alone are not sufficient for the development of blood cancers and this, has prompted our interest and search for additional mutations that cooperate with genetic rearrangements to cause leukemia. Scientists in our laboratory use a multidisciplinary approach that incorporates a variety of molecular tools, cell imaging, single-cell genomics and in vivo model systems to study the functional consequences of mutations in hematopoietic cells responsible in leukemic transformation.
Our discoveries help create a better understanding of the molecular etiology of acute leukemias and lead to improvements in the ability to diagnose, risk stratify, monitor, and treat these types of catastrophic diseases in children.
Dr. James R. Downing is the president and chief executive officer of St. Jude Children’s Research Hospital. He is an architect of the expansion of St. Jude clinical care and research programs in Memphis and around the globe. Dr. Downing is a critical contributor in markedly improving the cure rates of children with ALL, making a series of seminal discoveries that unraveled mechanisms of leukemogenesis and drug resistance. Dr. Downing was instrumental in launching the Pediatric Cancer Genome Project, which sequenced the normal and cancer genomes of over 800 pediatric patients and transformed the broader field of genomic medicine. Dr. Downing’s decades-long career at St. Jude has been highlighted by paradigm-shifting discovery and remarkable accomplishment.
A diverse and eclectic mix of molecular and developmental biologists and biochemists each contributing unique talents and mastery in different scientific areas